My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 247

    1.

    Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.

    Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R, Torella R, Cozzolino D.

    Diabetes Care. 2002 Nov;25(11):1909-13.PMID: 12401731 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

    Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.

    N Engl J Med. 2001 Sep 20;345(12):870-8.PMID: 11565519 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

    Lewis EJ, Lewis JB.

    Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.PMID: 14586737 [PubMed - indexed for MEDLINE]Related articles

    4.

    [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]

    Parving HH, Lehnert H, Brøchner-Mortensen J, Gomis R, Andersen S, Arner P.

    Ugeskr Laeger. 2001 Oct 1;163(40):5519-24. Danish. PMID: 11601118 [PubMed - indexed for MEDLINE]Related articles

    5.

    Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

    Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.

    Ann Intern Med. 2003 Apr 1;138(7):542-9.PMID: 12667024 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics.

    Llewelyn DE, Garcia-Puig J.

    J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):141-5.PMID: 15526250 [PubMed - indexed for MEDLINE]Related articles

    7.

    Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients.

    Ceriello A, Assaloni R, Da Ros R, Maier A, Quagliaro L, Piconi L, Esposito K, Giugliano D.

    Diabetologia. 2004 Sep;47(9):1535-40. Epub 2004 Aug 14.PMID: 15316606 [PubMed - indexed for MEDLINE]Related articles

    8.

    Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.

    Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH.

    Diabetes Care. 2004 Aug;27(8):1897-903.PMID: 15277414 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.

    Andersen S, Bröchner-Mortensen J, Parving HH; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group.

    Diabetes Care. 2003 Dec;26(12):3296-302.PMID: 14633817 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

    Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.

    Nephrol Dial Transplant. 2000 Apr;15(4):487-97.PMID: 10727543 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting]

    Lehnert H, Bramlage P, Pittrow D, Kirch W.

    MMW Fortschr Med. 2003 Oct 9;145 Suppl 3:81-7. German. PMID: 15490772 [PubMed - indexed for MEDLINE]Related articles

    12.

    Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

    Croom KF, Curran MP, Goa KL, Perry CM.

    Drugs. 2004;64(9):999-1028. Review.PMID: 15101793 [PubMed - indexed for MEDLINE]Related articles

    13.

    A clinical trial in type 2 diabetic nephropathy.

    Lewis EJ, Hunsicker LG, Rodby RA; Collaborative Study Group.

    Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S191-4.PMID: 11576953 [PubMed - indexed for MEDLINE]Related articles

    14.

    Transcapillary escape rate of albumin in type II diabetic patients. The relationship with microalbuminuria and hypertension.

    Nannipieri M, Penno G, Rizzo L, Pucci L, Bandinelli S, Mattei P, Taddei S, Salvetti A, Navalesi R.

    Diabetes Care. 1997 Jun;20(6):1019-26.PMID: 9167118 [PubMed - indexed for MEDLINE]Related articles

    15.

    A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

    Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M.

    Curr Med Res Opin. 2006 Nov;22(11):2095-100.PMID: 17076969 [PubMed - indexed for MEDLINE]Related articles

    16.

    Systematic review on urine albumin testing for early detection of diabetic complications.

    Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

    Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.PMID: 16095545 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.

    Strutz F, Bramlage P, Paar WD.

    Curr Med Res Opin. 2005 Sep;21(9):1433-40.PMID: 16197662 [PubMed - indexed for MEDLINE]Related articles

    18.

    Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Fassi R, Fogari R.

    Clin Ther. 2007 Apr;29(4):602-10.PMID: 17617283 [PubMed - indexed for MEDLINE]Related articles

    19.

    The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.

    Laffel LM, McGill JB, Gans DJ.

    Am J Med. 1995 Nov;99(5):497-504.PMID: 7485207 [PubMed - indexed for MEDLINE]Related articles

    20.

    Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group.

    N Engl J Med. 2001 Sep 20;345(12):851-60.PMID: 11565517 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity